Aikido Pharma Inc.

Dominari Holdings, Inc. is a biotechnology development company, which engages in the provision of diversified portfolio of small-molecule anticancer and antiviral therapeutics in development. Its oncology therapeutics includes treatments for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. It also creates a broad-spectrum antiviral platform, in which the lead compounds have activity against multiple viruses including Influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2, the cause of COVID-19. The company was founded by Gilbert V. Levin and M. Karen Levin in 1967 and is headquartered in New York, NY.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Dominari Holdings, Inc. engages in wealth management, investment banking, sales and trading, and asset management through its subsidiaries. It operates through the Dominari Financial and Legacy AIkido business segments. The Dominari Financial segment represents the company’s broker-dealer business, which is composed of mostly underwriting and transactional service activities. The Legacy AIkido segment includes Aikido Labs, which manages the investments holdings of the legacy entity. The company was founded by Gilbert V. Levin and M. Karen Levin in 1967 and is headquartered in New York, NY.

NEW YORK, June 4, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that positive Phase 1 testing data was presented at the 2021 ASCO Annual Meeting June 4, 2021.  The poster presentation of the data was by Dr. Scott Tagawa, a Professor of Medicine & Urology at Weill Cornell Medicine and an AIkido Pharma Scientific Advisory Board member.

AIkido Pharma Announces Positive Phase 1 Data Presented at ASCO on 225Ac-J591

New York, New York--(Newsfile Corp. - May 20, 2021) -  PCG Digital -- Anthony Hayes is an optimist, with good reason. The CEO of AIkido Pharmaceuticals (NASDAQ: AIKI), according to the company's Q1 report and a press release recently issued, is expecting positive results from human clinical trials of dual-action peptide receptor radionuclide therapy (PRRT) with notable insider buying in the open market displaying his strong belief in the Company's prospects.Developed by Weill Cornell Medicine...

AIkido Pharma Has Pending Data Results on June 4th, with Strongest Balance Sheet in Its History While Trading Below Cash

NEW YORK, May 20, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that Phase 1 testing data will be presented at the 2021 ASCO Annual Meeting June 4, 2021.  The presentation of the data will be by Dr. Scott Tagawa, a Professor of Medicine & Urology at Weill Cornell Medicine and an AIkido Pharma Scientific Advisory Board member.

AIkido Pharma Announces Phase 1 Data To Be Presented at the American Society of Clinical Oncology ("ASCO") Annual Meeting

New York, New York--(Newsfile Corp. - May 19, 2021) - PCG Digital -- Continuing the barrage of good-news announcements that began with its first quarter results and strong balance sheet reports, Alkido Pharma Inc. (NASDAQ: AIKI) was recently highlighted in two key investor features. A biotechnology company based in New York, Alkido Pharma is working to develop a diverse portfolio of early and mid-stage small-molecule anti-cancer therapeutics. The newsworthy company also partners with leading universities,...

AIKI Featured as Stock to Watch Ahead of Significant Key Milestones

Actinium Pharmaceuticals

Atossa Genetics

Bionano Genomics

CTI BioPharma

Immutep Ltd

Onconova Therapeutics

These seven risky Reddit penny stocks are in the biotech space and the business of developing cancer therapies and treatments. The post 7 Reddit Penny Stocks Promising to Cure Cancer appeared first on InvestorPlace.

7 Reddit Penny Stocks Promising to Cure Cancer

New York, New York--(Newsfile Corp. - May 13, 2021) - AIkido Pharma Inc. (NASDAQ: AIKI) today announced that Darrell G. Dotson, Vice President and General Counsel will be attending the Q2 Virtual Investor Summit.  Event Q2 Investor Summit Date May 17-18th, 2021 Presentation May 18th at 3:30 PM ET

AIkido Pharma Inc.: Invitation to the Q2 Virtual Investor Summit

New York, New York--(Newsfile Corp. - May 13, 2021) - PCG Digital -- Things seem to be heating up for (NASDAQ: AIKI) with a near term potential catalyst quickly approaching this quarter and several others planned throughout the remainder of the year. Management has been filing form 4s showing open market buying which typically signals strong faith in the company and signifies how undervalued they believe the stock may be at these levels. Speaking of...

AIKI's Near Term Catalyst Approaching this Quarter with Strong Cash Balance Sheet for Strategic Initiatives

NEW YORK, May 11, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") reported financial results for the first quarter ended March 31, 2021 and provided a corporate update. Anthony Hayes, CEO of AIkido Pharma, stated, "With testing data expected in this current quarter, we are excited about the results and the advancement of our technologies.

AIkido Pharma Inc. Announces First Quarter 2021 Results and Provides Corporate Update

Diffusion Pharmaceuticals

Biotech penny stocks are back in focus; should these 3 be on your watchlist? The post Top Biotech Penny Stocks on Reddit?

Top Biotech Penny Stocks on Reddit? Check These 3 Out

NEW YORK, April 26, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that Dr. Matthew Frieman has joined the Company's Scientific Advisory Board. "Dr. Frieman is a world-class scientist and inventor.

AIkido Pharma Announces Inventor and Scientist Dr. Matthew Frieman Joins Scientific Advisory Board

Brickell Biotech Inc

Kelso Technologies

Oragenics

Penny stocks on Robinhood are a big focus for Reddit traders in April The post 4 Reddit Penny Stocks To Buy On Robinhood For Under $1 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Reddit Penny Stocks To Buy On Robinhood For Under $1 Right Now

BIOLASE

Biotech stocks are more popular than ever; here are 3 to watch under $5 The post Biotech Penny Stocks To Buy? 3 to Watch Under $5 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Biotech Penny Stocks To Buy? 3 to Watch Under $5

NEW YORK, April 22, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that the Company has withdrawn its S-1 Registration Statement that was previously filed with the U.S. Securities and Exchange Commission ("SEC"). The Registration Statement has not been declared effective by the SEC, and no securities have been sold in connection with the offering described in the Registration Statement.

AIkido Pharma Announces Withdrawal of S-1 Registration Statement

Iterum Therapeutics Plc

Ovid Therapeutics

T2 Biosystems

Biotech penny stocks are all the rage; should you check these four out? The post 4 Biotech Penny Stocks To Watch That Are Heating Up This Month appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Biotech Penny Stocks To Watch That Are Heating Up This Month

NEW YORK, April 16, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today noted that a recent study announced positive early results from a PSMA 617-Lu177 study conducted by a leading global pharmaceutical company.  The report provides strong indications for analogous success in similar technology the Company is helping to develop.

AIkido Pharma Notes Advancement in Radiopharmaceutical Research

Aikido Pharma Inc (NASDAQ: AIKI) has been granted an exclusive sublicense to technology related to the use of the central nervous system (CNS) homing peptides to treat neuroinflammatory disease in cancer patients. The homing peptides covered by the sublicense can facilitate the delivery of therapeutic agents to inflamed CNS tissue.

Aikido Secures Sublicense For Psilocybin Treatment of Neuro-Inflamed Tissue in Cancer Patients

NEW YORK, April 7, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that it has been granted an exclusive sublicense to technology related to the use of novel and proprietary central nervous system (CNS) homing peptides for the therapeutic treatment of neuroinflammatory disease in cancer patients.   The homing peptides covered by the sublicense can be used to facilitate the delivery of therapeutic agents to inflamed CNS tissue.

AIkido Granted Sublicense to Technology for Targeted Psilocybin Treatment of Neuro-Inflamed Tissue in Cancer Patients

NEW YORK, April 5, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided a business update. Anthony Hayes, CEO of AIkido Pharma, stated, "AIkido's primary focus is the commercialization of improved treatments for multiple types of cancer and viral infections through innovative research and development that leverages the power of artificial intelligence and machine learning.

AIkido Pharma Provides Business Update

NEW YORK, March 29, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that it is sponsoring psychedelic research at the Mount Sinai Center for Psychedelic Psychotherapy and Trauma Research (the "Center"). The Center examines the therapeutic potential of psychedelic compounds for post-traumatic stress disorder (PTSD) and other trauma-related symptoms.

AIkido Pharma Sponsors Psychedelic Compound Research to Treat PTSD

NEW YORK, March 12, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that Dr. Matt Frieman appeared on the video podcast This Week in Virology, segment entitled "TWiV 729: A floret of spikes with Matt Frieman ."  In the video, Dr. Frieman discusses the Covid-19 pandemic from the point of view of a coronavirologist.

AIkido Pharma Announces Dr. Matt Frieman's Appearance on This Week in Virology

COMPASS Pathways

NEW YORK, Feb. 25, 2021 /PRNewswire/ -- The emergence of psychedelics as a mental health solution and as a legitimate industry has been one of the most radical market developments that we have seen in decades. Far from being a fleeting trend, the global psychedelics market is primed to...

First Movers in the Psychedelics Space Position Themselves as Industry Leaders

NEW YORK, Feb. 23, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that the underwriter of its previously announced bought deal offering of common stock has partially exercised its option to purchase an additional 7,030,927 shares of...

AIkido Pharma Inc. Announces Exercise of Option to Purchase Additional Shares in Bought Deal Offering

NEW YORK, Feb. 19, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced the closing of its previously announced underwritten public offering of 46,875,000 shares of its common stock at a price to the public of $1.60 per share. As previously...

AIkido Pharma Inc. Announces Closing of $75 Million Bought Deal Offering of Common Stock

Aikido Pharma Inc (NASDAQ: AIKI) has increased the size of the previously announced public offering to 46.8 million shares at $1.60 per share, with gross proceeds of $75 million. The previous offering included 6.25 million shares for gross proceeds of a mere $10 million.

Aikido Pharma Slumps On $75M Upsized Equity Offering Issued At 25% Discount

NEW YORK, Feb. 16, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 46,875,000 shares...

News for Aikido Pharma Inc. Stock (AIKI)